{"organizations": [], "uuid": "2ee3e9a7430b76a5ba884bea66b327860059f5cc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-fda-confirms-date-to-providing-reg/brief-fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch-idUSFWN1QP0IL", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-07T15:47:00.000+02:00", "replies_count": 0, "uuid": "2ee3e9a7430b76a5ba884bea66b327860059f5cc"}, "author": "", "url": "https://www.reuters.com/article/brief-fda-confirms-date-to-providing-reg/brief-fda-confirms-date-to-providing-regulatory-guidance-for-aequus-anti-nausea-patch-idUSFWN1QP0IL", "ord_in_thread": 0, "title": "BRIEF-FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch", "locations": [], "entities": {"persons": [{"name": "gui", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "aequus’ anti-nausea patch reuters", "sentiment": "none"}, {"name": "aequus pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7, 2018 / 1:50 PM / Updated 12 minutes ago BRIEF-FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch Reuters Staff March 7 (Reuters) - Aequus Pharmaceuticals Inc: * FDA CONFIRMS DATE TO PROVIDING REGULATORY GUIDANCE FOR AEQUUS’ ANTI-NAUSEA PATCH * AEQUUS PHARMACEUTICALS - FDA WILL PROVIDE FEEDBACK TO CO’S PRE-INVESTIGATIONAL NEW DRUG SUBMISSION BY APRIL END, 2018 FOR AQS1303​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-07T15:47:00.000+02:00", "crawled": "2018-03-07T16:12:43.008+02:00", "highlightTitle": ""}